Search

Displaying results 4841 - 4850 of 6198 in total
  1. Drug

    TAK-751S

    go.drugbank.com/drugs/DB06432
    Investigational

    TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]

    Synonyms: Synsorb Pk, Synsorb-Pk
  2. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  3. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.

  4. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

    Products: VISTAGAN LIQUIFILM 0.5%O K
  5. Drug

    MGD-024

    go.drugbank.com/drugs/DB17265
    Investigational

    MGD-024 is an anti-CD123/anti-CD3 bispecific DART molecule.

  6. Drug

    MEDI-547

    go.drugbank.com/drugs/DB18360
    Investigational

    MEDI-547 is an anti-EphA1 monoclonal antibody conjugated to mcMMAF

  7. Drug

    Norvaline

    go.drugbank.com/drugs/DB04185
    Investigational

    Norvaline is an isomer of the more common amino acid valine.

  8. Drug

    Tazarotene

    go.drugbank.com/drugs/DB00799
    Approved

    Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and...

  9. Drug

    NM3086

    go.drugbank.com/drugs/DB17719
    Experimental

    NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.[L46193]

  10. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.